Spravato Treatment for Depression

What it is

Spravato (esketamine) is an FDA-approved nasal spray for adults with treatment-resistant depression. It is administered only in a certified medical setting due to required observation. Official info: https://www.spravato.com

Why it’s offered

Some patients do not respond to standard antidepressants. Spravato provides an alternative mechanism of action and has been shown to reduce depressive symptoms for many individuals with treatment-resistant depression.

How it works

Spravato affects NMDA receptors and may help restore neural pathways involved in mood regulation. After dosing, patients are monitored in-clinic for two hours due to predictable short-term effects.

What treatment includes

Psychiatric evaluation and eligibility screening

In-office dosing supervised by a licensed provider

Two-hour monitoring period

Ongoing follow-up and coordination with the patient’s mental health team

Important notes

Spravato cannot be taken home. It must be part of a comprehensive depression treatment plan that includes therapy and medication management.